(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/05749 A1

(51) International Patent Classification[7]: C07C 271/06, A61K 31/27

(21) International Application Number: PCT/DK00/00386

(22) International Filing Date: 11 July 2000 (11.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/144,063 16 July 1999 (16.07.1999) US

(71) Applicant *(for all designated States except US)*: LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) [DK/DK]; Industriparken 55, DK-2750 Ballerup (DK).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: OTTOSEN, Erik, Rytter [DK/DK]; Lotusvej 6, DK-3650 Ølstykke (DK). DANNACHER, Heinz, Wilhelm [CH/DK]; Bøgesvinget 29, DK-2740 Skovlunde (DK).

(74) Agent: THALSØ-MADSEN, Birgit; Leo Pharmaceutical Products Ltd. A/S, Patent Department, Industriparken 55, DK-2750 Ballerup (DK).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-α



(I)

(57) Abstract: The present invention relates to compounds of formula (I) wherein R_1, R_2 and R_3 independently represent one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, carbamoyl, or phenyl; R_1 and R_2 further represented by nitro and R_3 by carboxy; R_4 represents hydrogen, (C_1-C_3)alkyl, or allyl; Q represents a bond, or -C(R_6)(R_7)(-O-C=O)-, in which formula R_6 and R_7 independently represent hydrogen, trifluoromethyl, or (C_1-C_4)alkyl; Y represents either (C_5-C_{15})alkyl, (C_2-C_{15})olefinic group, (C_3-C_{10})monocyclic hydrocarbon, or phenyl, any of which may be optionally substituted with one or more, same or different substituents represented by the formula R_5; or (C_1-C_4)alkyl substituted with at least one or more substituents with the formula R_5; or Y represents a group of formula -CH_2-(Z-O)$_n$-Z where Z is a (C_1-C_3)alkyl, where n is a integer > 1 and no continuous linear sequence of atoms in the group Y > 15; R_5 represents halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, azido, nitro, -COOH, -$CONH_2$, -CONHR', or -COONR'R' wherein R' stands for (C_1-C_3)alkyl; X represents oxygen or sulphur, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The compounds are valuable in the human and veterinary therapy.

WO 01/05749 A1

583

AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-α

FIELD OF THE INVENTION

This invention relates to a hitherto unknown class of compounds which shows anti-inflammatory effects, to pharmaceutical preparations containing these compounds, to dosage units of such preparations, and to their use in the treatment and prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis and atopic dermatitis, uveitis, septic shock, AIDS, and acne.

BACKGROUND OF THE INVENTION

Previously, a series of closely related aminobenzophenones (e.g. 4-(2-amino-4-nitrophenylamino)benzophenone) have been described (Hussein, F.A. *et al*, Iraqi J. Sci., 22, 54-66 (1981)). However, there is no description of their uses. PCT/DK98/00008 discloses aminobenzophenone inhibitors of interleukin 1β (IL-1β) and tumour necrosis factor a (TNF-α) secretion *in vitro*, said compounds being potentially useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis, e.g. asthma, rheumatoid arthritis, psoriasis, contact dermatitis, and atopic dermatitis. Furthermore the compounds of PCT/DK98/00008 was tested *in vivo* for anti-inflammatory properties in the 12-*O*-tetradecanoylphorbol-13-acetate (TPA) induced murine chronic skin inflammation model, (De Young, L.M. et al, Agents Actions, 26, 335-341 (1989); Carlson, R.P. et al, Agents Actions, 17, 197-204 (1985); Alford, J.G. et al, Agents Action, 37, (1992); Stanley, P.L. et al, Skin Pharmacol, 4, 262-271 (1991)). In this chronic skin inflammation model the compounds had the same potency compared to the reference compound hydrocortisone.

The purpose of the present invention is to provide further pharmacologically active aminobenzophenone derivatives and related compounds.

This purpose is achieved with the novel aminobenzophenone derivatives according to the general formula I that are potent inhibitors of interleukin 1β (IL-1β) and tumour necrosis factor α (TNF-α) secretion *in vitro*, making them potentially useful for treatment of inflammatory diseases, in which the secretion and regulation of cytokines or more specifically interleukin 1β (IL-1β) and tumour necrosis factor α (TNF-α) are involved in the pathogenesis. The inhibition or down regulation of the cytokines is possibly due to an inhibition of MAP kinases.

SUMMARY OF THE INVENTION

The compounds of the present invention are represented by the general formula I below



I

wherein R_1 and R_2 independently represents one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, carbamoyl, phenyl, or nitro;

R_3 represents hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)-alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, phenyl, cyano, carboxy, or carbamoyl;

R_4 represents hydrogen, (C_1-C_3)alkyl, or allyl;

Q represents bond, or -C(R_6)(R_7)(-O-C=O)-, in which formula R_6 and R_7 stands for hydrogen, trifluoromethyl, or (C_1-C_4)alkyl;

Y represents either (C_5-C_{15})alkyl, (C_2-C_{15})olefinic group, (C_3-C_{10})monocyclic hydrocarbon, or phenyl, any of which may be optionally substituted with one or more, same or different substituents represented by the formula R_5; or (C_1-C_4)alkyl substituted with at least one or more substituents with the formula R_5; or Y represents a group of formula -CH_2-(Z-O)$_n$-Z where Z is a (C_1-C_3)alkyl, where n is a integer > 1 and no continuous linear sequence of atoms in the group Y > 15;

R_5 represents halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, azido, nitro, -COOH, -$CONH_2$, -CONHR', or -COONR'R' wherein R' stands for (C_1-C_3)alkyl;

X stands for oxygen or sulphur;

and salts thereof with pharmaceutically acceptable acids, hydrates and solvates thereof.

DETAILED DESCRIPTION OF THE INVENTION

Preferred embodiments of the invention:

In compounds of formula I R_1 preferably represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, trifluoromethyl, amino, (C_1-C_2)alkyl, (C_2-C_3)alkenyl, (C_1-C_3)alkoxy, (C_1-C_3)alkoxy-carbonyl, or cyano. R_2 preferably represents one or more, same or different substituents selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, trifluoro-methyl, amino, (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_1-C_3)alkoxy. R_3 preferably represents one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, trifluoromethyl, (C_1-C_3)alkyl, (C_2-C_3)alkenyl, (C_1-C_3)-alkoxy, (C_1-C_3)alkoxycarbonyl, cyano, or carboxy. R_4 preferably represents hydrogen, (C_1-C_2)alkyl, or allyl. X preferably represents oxygen. Q preferably represents a bond or -CH_2-O-C=O- .

More preferably Y represents (C_1-C_4)alkyl substituted with one or more, same or different substituents selected from the group represented by halogen, hydroxy, amino, (C_1-C_2)-alkoxy, (C_1-C_4)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, azido, -COOH, -$CONH_2$, -CONHR', or -CONRR' wherein R and R' represent (C_1-C_2)alkyl; or Y represents (C_5-C_6)alkyl; (C_2-C_6)alkenyl; (C_3-C_6)cycloalkyl; (C_5-C_8)cycloalkene group; or phenyl; any of which is optionally substituted with one or more, same or different substituents selected from the group represented by halogen, hydroxy, amino, (C_1-C_2)alkoxy, (C_1-C_4)alkyl-amino, (C_1-C_3)alkoxycarbonyl, cyano, azido, -COOH, -$CONH_2$, -CONHR', or -CONRR' wherein R and R' represent (C_1-C_2)alkyl.

It is even more preferred that R_1 represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, methyl, or methoxy, and that R_1 represents one substituent in the 2-position, preferably R_1 is 2-methyl. R_2 most preferably represents one or more, same or different substituents selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, methyl, or methoxy, and R_2 represents one substituent in the 2-position, most preferably R_2 is 2-Cl. R_3 and R_4 most preferably represent hydrogen. Y most preferably represents (C_1-C_4)alkyl substituted with halogen, hydroxy, amino, cyano, azido, and -COOH, or Y represents (C_5-C_6)alkyl, (C_5-C_6)carbocyclic group, or phenyl any of which may be optionally substituted with one or more, same or different substituents selected from the group consisting of chloro, bromo, hydroxy, amino, azido, (C_1-C_2)alkoxycarbonyl, cyano, -COOH, -$CONH_2$, $CON(CH_3)_2$.

Most preferably Y represents methyl, 1-chloro-methyl, 2-azido-ethyl, hexyl, 6-chloro-hexyl, or phenyl.

Specific compounds of the invention are:

Hexyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 101),
6-Chloro-hexyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 102),
Phenyl *N*-[2-(4-benzoylphenylamino)phenyl]carbamate (Compound 103),
2-Azido-ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 104),
Phenyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 105),
1-Chloromethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 106),
Cyclopentyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 107),
Cyclohexyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 108),
1-Acetoxymethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 109),
Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,3-dimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 110),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-*n*-butyl-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 111),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-chloro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 112),

Cyclopentyl *N*-[5-bromo-2-[3-fluoro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 113),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,4,5-trimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 114),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-fluoro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 115),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,5-dimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 116),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(3-chloro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 117),

Cyclopentyl *N*-[5-bromo-2-[3-fluoro-4-(4-methoxy-2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 118),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-ethoxy-2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 119),

Cyclopentyl *N*-[5-bromo-2-[3-ethoxy-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 120),

1-(3-(Methoxycarbonyl)propanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenyl-amino]phenyl]carbamate (Compound 121),

1-(3-(Methoxycarbonyl)propanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenyl-amino]phenyl]carbamate (Compound 122),

1-(3-Carboxypropanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 123),

1-(3-Carboxypropanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 124),

1-(hexanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 125),

1-(3-(Methoxycarbonyl)propanoyloxy)methyl *N*-[5-bromo-2-[3-chloro-4-(2-methyl-benzoyl)-phenylamino]phenyl]carbamate (Compound 126),

1-(3-Carboxypropanoyloxy)methyl *N*-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 127),

1-Chloromethyl *N*-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 128),

and salts thereof with pharmaceutically acceptable acids, hydrates and solvates.

Further preferred compounds of general formula I are compounds wherein R_1, R_2, and R_3 represent one substituent, R_1 and R_2 preferably being in the ortho position.

As used in the specification, unless specified to the contrary, the following terms have the meaning indicated:

"Alkyl" refers to any univalent group derived from an alkane by removal of a hydrogen atom from any carbon atom, and includes the subclasses of normal alkyl (*n*-alkyl), and primary, secondary and tertiary alkyl groups respectively, and having the number of carbon atoms specified, including for example (C_1-C_3)alkyl, (C_1-C_4)alkyl, (C_5)alkyl, (C_5-C_{15})alkyl, (C_6-C_{10})alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl. Alkane refers to an acyclic branched or unbranched hydrocarbon having the general formula C_nH_{2n+2}, and therefore consisting entirely of hydrogen atoms and saturated carbon atoms.

"Olefinic group" refers to a straight or branched acyclic hydrocarbon having one or more carbon-carbon double bonds of either E or Z stereochemistry where applicable, and having the number of carbon atoms specified. The term includes, for example, (C_2-C_{15})olefinic group, preferably a (C_2-C_{15})alkenyl; (C_2-C_3)olefinic group, preferably a (C_2-C_3)alkenyl; vinyl; allyl; 1- butenyl; 2-butenyl; and 2-methyl-2-propenyl. Olefinic groups having only one carbon-carbon double bond, herein called alkenyl, are preferred.

"Alkoxy" refers broadly to a radical of the formula -OR, where R is alkyl as defined above, for example example (C_1-C_3)alkoxy, (C_1-C_2)alkoxy, methoxy, ethoxy, n-propoxy, and the like.

"(C_1-C_3)alkylthio" refers broadly to a radical of the formula -SR, where R is alkyl as defined above and includes methylthio, ethylthio, n-propylthio, and 2-propylthio.

"(C_1-C_6)alkylamino" refers broadly to a radical of the formula -NHR or -NR_2, where R is alkyl as defined above having from 1-6 carbon atoms and includes, for example, methyl-amino, dimethylamino, di-(n-propyl)amino, and n-butyl(ethyl)amino.

"(C_1-C_3)alkoxycarbonyl" refers broadly to a radical of the formula -COOR, where R is alkyl as defined above and includes methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, and i-propoxycarbonyl.

"(C_3-C_{10})monocyclic hydrocarbon group" includes the saturated cycloalkanes and unsaturated cyclic olefins, such as cycloalkenes having one endocyclic double bond, and having from 3-10 carbon atoms, and includes, for example, (C_3-C_8)cycloalkyl, cyclopropyl, cyclopentyl, cyclohexyl, and cyclooctyl, (C_3-C_{10})cycloalkene group, and (C_3-C_8)cycloalkene group. Specific examples are cycloprop-2-enyl, cyclobut-2-enyl, cyclopent-2-enyl, cyclohex-3-enyl, and cyclonon-4-enyl.

"Amino" means the group -NH_2.

"Carbamoyl" refers to any one of the groups -$CONH_2$, -CONHR, and -CONRR' where R and R' represent alkyl as defined above.

"Carboxy" refers to a radical of the formula -COOH.

"Halogen" means the same or different of fluoro, chloro, bromo, and iodo; fluoro, chloro, and bromo being preferred.

The phenyl group of R_1 and R_2 may optionally be substituted, e.g. with hydroxy; amino; nitro; cyano; halogen, preferably fluoro, chloro, or bromo; methyl; or methoxy.

The compounds of the invention can be used in the form of their salts which are formed with pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, hydrobromic and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, p-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid propionic acid, citric acid, tartaric acid, succinic acid, benzoic acid, maleic acid, these examples being considered as non-limiting for the invention.

Pharmacological methods

To study the effect of the compound of the present invention in vitro the inhibition of the IL-1β and TNF-α secretion was measured using the following procedure:

Cytokine production was measured in the media from lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells. The mononuclear cells were isolated from human peripheral blood by Lymphoprep® (Nycomed, Norway) fractionation and suspended in

RPMI 1640 (growth medium) with foetal calv serum (FCS, 2%), at a concentration of 5 x 10^5 cells/ml. The cells were incubated in 24-well tissue culture plates in 1 ml aliquots. Test compounds were dissolved in dimethylsulfoxide (DMSO, 10 mM) and were diluted with the medium. Compounds were added to the cells for 30 minutes, then LPS (1 mg/ml final concentration) was added. The plates were incubated for 18 hours, and the concentration of IL-1β and TNF-α in the medium was determined by enzyme-linked immunosorbent assays. The median inhibitory concentrations (IC_{50}) of the compounds were calculated. The results are shown in Table 1.

The compounds of the present invention also show similar activities in the ability to inhibit PMN (polymorphonuclear) superoxide secretion which is also indicative of potentially useful anti-inflammatory drugs. The compounds were tested using the following procedure:

Human polymorphonuclear (PMN) granulocytes were isolated from human blood by dextran sedimentation, Lymphoprep® fractionation and hypotonic lysis of contaminating erythrocytes.

Superoxide anion generation was measured as the superoxide dismutase inhibitable reduction of ferricytochrome C (Madhu, S.B. et al, Inflammation, 16, 241, (1992)). The cells were suspended in Hanks' balanced salt solution, and incubated for 10 minutes at 37°C with test compounds. The cells were primed by the addition of TNF-α (3 ng/ml final concentration) for 10 minutes, and then ferricytochrome C, (final concentration 750µg/ml), bovine serum albumin (BSA, final concentration 1 mg/ml) and formyl-methionyl-leucyl-phenylalanine (fMLP, final concentration 10^{-7} M) were added for 3 minutes. The cells were chilled on ice, and were spun down. The optical densities in the cell-free supernatant was measured in a spectrophotometer. The median inhibitory concentration (IC_{50}) of the compounds was calculated. The results are shown in Table 1.

Table 1

	Inhibition of cytokines and PMN-superoxide production in vitro by compounds of the present invention.		
	The median inhibition concentration (IC_{50}, nM) of		
Comp. No.	IL-1β	TNF-α	PMN-superoxide
105	50	10	100

	Inhibition of cytokines and PMN-superoxide production in vitro by compounds of the present invention.		
	The median inhibition concentration (IC_{50}, nM) of		
Comp. No.	IL-1β	TNF-α	PMN-superoxide
109	32	6.3	40
ref. a)	13	7.1	5.0
ref. b)	32	5.0	5.0

ref. a): 4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone, compound 106 disclosed in PCT/DK98/00008. ref b): Ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate, compound 173 disclosed in PCT/DK98/00008.

These results show that the compounds of the present invention are able to inhibit the production of IL-1β, TNF-α and PMN-superoxide, thus making them potentially useful in the treatment of inflammatory diseases.

To study the compounds of the present invention *in vivo* the 12-*O*-tetradecanoylphorbol-13-acetate (TPA) induced murine chronic skin inflammation model can be used (De Young, L.M. et al, Agents Actions, 26, 335-341 (1989); Carlson, R.P. et al, Agents Actions, 17, 197-204 (1985); Alford, J.G. et al, Agents Action, 37, (1992); Stanley, P.L. et al, Skin Pharmacol, 4, 262-271 (1991)), cf. description of method in PCT/DK98/00008 hereby incorporated by reference. These results shows that the compounds of the present invention are of the same potency compared to known reference compounds, e.g. hydrocortisone with its known side effects, whereas the compounds of the present invention are well tolerated and are non-toxic. Some members of the present class of compounds show a very low absorption, thus making them especially useful in the treatment of various dermatological diseases. In general, they may be administered by e.g. oral, intravenous, intranasal, topically or transdermal routes.

Method of preparation

The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis. The compounds of the present invention can be synthesised using the methods outlined below, together with methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.

The novel compounds of formula I may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment and work-up procedures, are chosen to be conditions of standard for that reaction, which should be readily recognised by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the educt molecule must be compatible with the reagents and reactions proposed. Not all compounds of formula I falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods can be used.



and R_1, R_2, R_3, R_4, X, and Y have the above meanings.

Scheme 1

Compounds according to the present invention may be prepared by a process comprising coupling of an amine of the formula II with an chloroformate ester, 4-nitrophenylformate ester, or other suitable activated derivatives of the formula III, as shown in scheme 1,

where R_1, R_2, R_3, R_4, Q, X, and Y are as defined in general formula I, except that any substituents or functional group which are potentially reactive in the coupling reaction may themselves be protected before the coupling reaction is performed and subsequently removed.

Especially in the case were Q represents bond compounds of the present invention may conveniently be prepared by a process were the reactive intermediate of the formula III is first formed *in situ* from the corresponding alcohol of the general formula IV, e.g. by treatment with phosgene, bis(trichloromethyl) carbonate, di(2-pyridyl) carbonate, or the like, and then treated with the amine of the general formula II, where R_1, R_2, R_3, R_4, X, and Y are as defined in general formula I, except that any substituents or functional group which are potentially reactive in the coupling reaction may themselves be protected before the coupling reaction is performed and subsequently removed.

Compounds accordingly to the present invention with the general formula II(X=O) may be prepared by several methods known to those skilled in the art of organic synthesis. One useful sequence is shown in scheme 2 were the key process comprising coupling of an amine of the formula VII with an fluoride, chloride, bromide, iodide, or triflate with the formula VIII, as shown in Scheme 2, where R_1, R_2, R_3, and, R_4 are as defined in general formula I, to give a coupled product with the general formula VI, except that any substituents or functional group which are potentially reactive in the coupling reaction may themselves be protected before the coupling reaction is performed and subsequently removed. This compound VI may then be reduced to the corresponding amine with the general formula II by treatment with standard reducing agents. Examples of such reducing agents include, but are not limited to, stannous chloride dihydrate; hydrogen, ammonium formiate, or hydrazine hydrate and a catalytic amount of palladium on carbon.



and R_1, R_2, R_3, and R_4 have the above meanings.

Scheme 2

The coupling reaction is carried out using any of the methods for the formation of diphenylamines known to one skilled in the art of organic synthesis. The preferred method is the nucleophilc aromatic substiution method which comprising coupling of an amine with an arylfluoride or arylchloride in the presence of a base, in an suitable solvent.

Especially potassium-*tert*-butoxide (KO*t*-Bu), sodium-*tert*-butoxide (NaO*t*-Bu), sodium hydrid (NaH), and potassium hydride (KH) have proven to be the best bases in this process, but other bases may be used as well.

The reaction is typically performed at ambient temperature (20-25 ^{o}C) in dipolar aprotic solvents like dimethylsulfoxide (DMSO), dimethylformamide (DMF), or *N*-methylpyrrolidone (NMP) under an inert atmosphere like argon or nitrogen.

Alternatively, the coupling reaction can be done by the palladium catalysed amination method which comprising coupling of an amine with an arylhalogenide (iodide, bromide, triflate, or in some cases chloride) in the presence of a base, a suitable Pd source, and a suitable phosphine ligand in an inert solvent.

The palladium compound used in the process is not particularly limited, and as specific examples are palladium(II) acetate, palladium(II) chloride, palladium(II) bromide, dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), tris(dibenzylideneacetone)dipalladium(0). The preferred ligand include, but are not limited to, racemic or non-racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (hereinafter referred to as BINAP), tri-o-tolylphosphine, tri-tert-butylphosphine, 1,1'-bis(diphenylphosphino)-ferrocene, bis[(2-diphenylphosphino)phenyl]ether (DPEphos), 2-dicyclohexylphosphanyl-2'-dimethylaminobiphenyl, 2-(di-*tert*-butylphosphino)biphenyl, and 9,9-dimethyl-4,6-bis(diphenylphosphino)xanthene (Xantphos). The amount of palladium and ligand used in this process is typically in the range 0.1 to 10 % by mole relative to the amount of the aromatic halide (or triflate) used. Especially sodium-*tert*-butoxide (NaO*t*-Bu) and caesium carbonate (Cs_2CO_3) have proven to be the best bases in this process, but other bases may be used as well. The reaction is typically performed at elevated temperature (80-120 ^{o}C) in inert solvents like 1,4-dioxane, toluene, benzene and tetrahydrofurane under an inert atmosphere like argon or nitrogen.

Compounds according to the present invention in which R_4 is not hydrogen may be prepared by a process comprising coupling of an amine of the formula VI (R_4= H) with an alkylating agent, as shown in scheme 2, where R_1, R_2, R_3, and, R_4 are as defined in general formula I, except that any substituents or functional group which are potentially reactive in the coupling reaction may themselves be protected before the coupling reaction is performed and subsequently removed.

Typically alkylating agents of the general formula R-Y include, but are not limited to,

iodides (Y=I), bromides (Y=Br), chlorides (Y=Cl) and sulfonates ($Y=OSO_2R'$, where R' represents methyl, trifluoromethyl or 4-methylphenyl).

Compounds according to the present invention may in special cases be prepared by a simple functional group interconversion (FGI), meaning a standard process, known to those skilled in the art of organic synthesis, where a functional group in compounds with the general formula I (or any other intermediate described herein) is transformed into a different functional group in one or more synthetic steps, leading to a new compound with the general formula I. Examples of such processes are, but are not limited to, hydrolysis of an ester to give an acid under basic conditions; deprotection of an methylether to give an phenol by treatment with e.g. borontribromide (BBr_3); and catalytic hydrogenation of an olefin to give an saturated hydrocarbon.

Compounds according to the present invention in which C=X represents -(CS)- may be prepared from compounds of the invention (or any other intermediate described herein) in which C=X represents -(CO)- by a process using an appropiate thiocarbonylating agent such as phosphorous pentasulfide (P_4S_{10}), or Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiaphosphetane-2,4-disulfide) or the like.



hal: Br, I

and R_1, and R_2 have the above meanings.

SCHEME 3

Compounds accordingly to the present invention with the general formula VII may be prepared by several methods known to those skilled in the art of organic synthesis. One useful sequence is shown in Scheme 3. The key step comprises coupling of a bromide (or iodide) with the general formula X with an acid chloride with the general formula XI to afford the benzophenone with the general formula IX. This compound IX may then be reduced to the corresponding amine with the general formula VII by treatment with standard reducing agents. Examples of such reducing agents include, but are not limited to, stannous chloride dihydrate; hydrogen, ammonium formiate, or hydrazine hydrate and a catalytic amount of palladium on carbon. The coupling reaction is done by transforming the bromide (X) into a reactive organometallic intermediate, e.g. by treatment with butyllithium to afford the lithium derivative or by treatment with magnesium to afford the magnesium derivative. The reactivity of this intermediate is then modulated by transme-

tallation to e.g. zinc, by treatment with $ZnCl_2$, $ZnBr_2$, or ZnI_2. This organozinc compound is then coupled with the acid chloride, with the general formula XI, under the influence of a palladium(0) complex in catalytic amount. Examples of such catalyst include but are not particularly limited to tetrakis(triphenylphosphine)palladium(0), tetrakis(triphenylarsine)-palladium(0), dichlorobis(triphenylphosphine)palladium(II), or benzylchlorobis(triphenyl-phosphine)palladium(II).

It may be more advantageous in some cases to alter the sequence of the processes described above. The described sequence of processes is not considered as being limited for the preparation of the compounds of the present invention with the general formula I and alteration of the reaction sequence is an obvious alternative for those skilled in the art of organic synthesis.

The present compounds are intended for use in pharmaceutical compositions which are useful in the treatment of the above mentioned diseases.

The amount required of a compound of formula I (hereinafter referred to as the active ingredient) for therapeutic effect will, of course, vary both with the particular compound, the route of administration and the mammal under treatment. A suitable dose of a compound of formula I for systemic treatment is 0.1 to 200 mg/kg bodyweight, the most preferred dosage being 0.2 to 50 mg/kg of mammal bodyweight, administered one or more times daily.

While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation. Conveniently, the active ingredient comprises from 0.1% to 100% by weight of the formulation. Conveniently, dosage units of a formulation contain between 0.07 mg and 1 g of the active ingredient. For topical administration, the active ingredient preferably comprises from 1% to 20% by weight of the formulation but the active ingredient may comprise as much as 50% w/w. Formulations suitable for nasal or buccal administration may comprise 0.1% to 20% w/w. for example about 2% w/w of active ingredient.

By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.

The formulations, both for veterinary and human medical use, of the present invention

comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

The formulations include those in a form suitable for oral, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular and intravenous), transdermal, intra-articular, topical, nasal, or buccal administration.

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient may also be administered in the form of a bolus, electuary or paste.

Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.

Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.

Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the active ingredient which may be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems may also be used to present the active ingredient for both intra articular and ophthalmic administration.

Formulations suitable for topical administration, including eye treatment, include liquid or

semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops.

Formulations suitable for administration to the nose or buccal cavity include powder, self-propelling and spray formulations, such as aerosols and atomizers.

In addition the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients.

The compositions may further contain other therapeutically active compounds usually applied in the treatment of the above mentioned pathological conditions, for instance glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticolinergic agents, methyl xanthines, β-adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

The novel compounds of the invention are of value in the human and veterinary practice as systemic and topical therapeutic agents for the treatment and prevention of diseases. The novel compounds show anti-acne properties and, i.a., anti-inflammatory and cytokine regulating effects possibly due to MAP kinase inhibition, and are useful in the treatment and prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondylo-arthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, and osteoporosis.

The invention will now be further described in the following non-limiting general procedures, preparations and examples.

EXAMPLES

General procedures, preparations and examples

The exemplified compounds I are listed in Table 2.

All melting points are uncorrected. For ^{1}H and ^{13}C nuclear magnetic resonance (NMR) spectra (300 MHz) chemical shift values (δ) (in ppm) are quoted, unless otherwise specified, for deuteriochloroform and hexadeuterodimethylsulfoxide solutions relative to

internal tetramethylsilane (δ 0.00) or chloroform (^{1}H NMR δ 7.25, ^{13}C NMR δ 76.81). The value for a multiplet (m), either defined (doublet (d), triplet (t), quartet (q)) or not at the approximate mid point is given unless a range is quoted (s singlet, b broad). The organic solvents used were anhydrous. The term "chromatography" refers to column chromatography using the flash technique and was performed on silica gel.

The following abbreviations have been used througout:

AgOAc	Silver acetate
Acetone-d_6	Hexadeuteroacetone
BTC	Bis(trichloromethyl) carbonate
$CDCl_3$	Deuteriochloroform
DMF	*N*,*N*-Dimethylformamide
DMSO-d_6	Hexadeuterodimethylsulfoxide
Et_3N	Triethylamine
EtOAc	Ethyl acetate
Et_2O	Diethylether
HMPA	Hexamethylphosphorous triamide
Me	Methyl
NMM	*N*-Methylmorpholine
THF	Tetrahydrofurane
TLC	Thin layer chromatography

Table 2 Compounds of general formula I

Comp. No.	Ex. No	X	R_1	R_2	R_3	R_4	Q	Y
101	1	O	2-CH_3	2-Cl	H	H	Bond	-$(CH_2)_5CH_3$
102	2	O	2-CH_3	2-Cl	H	H	Bond	-$(CH_2)_6Cl$
103	3	O	H	H	H	H	Bond	-phenyl
104	4	O	2-CH_3	2-Cl	H	H	Bond	-$(CH_2)_2N_3$
105	5	O	2-CH_3	2-Cl	H	H	Bond	-phenyl
106	6	O	2-CH_3	2-Cl	H	H	Bond	-$(CH_2)Cl$
107	7	O	2-CH_3	2-Cl	H	H	Bond	-cyclopentyl
108	8	O	2-CH_3	2-Cl	H	H	Bond	-cyclohexyl
109	9	O	2-CH_3	2-Cl	H	H	-CH_2-O-C=O-	-CH_3
110	10	O	2-CH_3, 3-CH_3	2-Cl	4-Br	H	Bond	-cyclopentyl
111	11	O	2-CH_3, 4-$(CH_2)_3CH_3$	2-Cl	4-Br	H	Bond	-cyclopentyl
112	12	O	2-CH_3, 4-Cl	2-Cl	4-Br	H	Bond	-cyclopentyl
113	13	O	2-CH_3	2-F	4-Br	H	Bond	-cyclopentyl
114	14	O	2-CH_3, 4-CH_3, 5-CH_3	2-Cl	4-Br	H	Bond	-cyclopentyl
115	15	O	2-CH_3, 4-F	2-Cl	4-Br	H	Bond	-cyclopentyl
116	16	O	2-CH_3, 5-CH_3	2-Cl	4-Br	H	Bond	-cyclopentyl
117	17	O	2-CH_3, 3-Cl	2-Cl	4-Br	H	Bond	-cyclopentyl
118	18	O	2-CH_3, 4-OCH_3	2-F	4-Br	H	Bond	-cyclopentyl
119	19	O	2- CH_3, 4-OCH_2CH_3	2-Cl	4-Br	H	Bond	-cyclopentyl
120	20	O	2-CH_3	2-OCH_2CH_3	4-Br	H	Bond	-cyclopentyl
121	21	O	2-CH_3	2-Cl	H	H	-CH_2-O-C=O-	-$CH_2CH_2COOCH_3$
122	22	O	2-CH_3	2-Cl	H	H	-$CHCH_3$-O-C=O-	-$CH_2CH_2COOCH_3$
123	23	O	2-CH_3	2-Cl	H	H	-CH_2-O-C=O-	-CH_2CH_2COOH
124	24	O	2-CH_3	2-Cl	H	H	-$CHCH_3$-O-C=O-	-CH_2CH_2COOH
125	25	O	2-CH_3	2-Cl	H	H	-CH_2-O-C=O-	-$(CH_2)_4CH_3$
126	26	O	2-CH_3	2-Cl	4-Br	H	-CH_2-O-C=O-	-$CH_2CH_2COOCH_3$

Comp. No.	Ex. No	X	R_1	R_2	R_3	R_4	Q	Y
127	27	O	2-CH_3	2-Cl	4-Br	H	-CH_2-O-C=O-	-CH_2CH_2COOH
128	28	O	2-CH_3	2-Cl	4-Br	H	-CH_2-O-C=O-	-CH_2Cl

The numbering in Table 2 refers to the numbering in the formula below



General procedure 1

Coupling of compounds of the general formula II with compounds of the general formula III to give compounds of the general formula I (Q=O) , or a protected derivative thereof.

To a cooled (0 °C) solution of an amine (1.0 mmol), with the general formula II, and *N*-ethyl diisopropylamine (1.0 mmol) in CH_2Cl_2 (10 ml) was slowly added a chloroformate (1.2 mmol), with the general formula III. Stirring was continued at room temperature for 24 h or until the starting material had disappeared as seen on TLC. The reaction mixture was concentrated *in vacuo* to afford the crude product. The crude product was either purified by chromatography and/or crystallized to give the title compound.

General procedure 2

Coupling of compounds of the general formula II with compounds of the general formula IV (via compounds of the general formula III to give compounds of the general formula I (Q=O) , or a protected derivative thereof.

To a stirred solution of an alcohol (1.0 mmol), with the general formula IV, in CH_2Cl_2 (3.0 ml) were added BTC (0.40 mmol) and pyridine (1.0 mmol) in CH_2Cl_2 (3.0 ml) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2 h. The solvent was removed *in vacuo* at 30 °C and the residue dissolved in EtOAc (10 ml) and stirred for

30 min. The precipitate was filtered off and the solvent removed *in vacuo* at 30 °C to give the crude chloroformate, with the general formula III. CH_2Cl_2 (5.0 ml) was added and the solution cooled to 0 °C. An amine (0.50 mmol), with the general formula II, and K_2CO_3 (2.0 mmol) were added and the reaction mixture was stirred for 24 h at room temperature. The reaction mixture was poured into water and extracted with CH_2Cl_2 or Et_2O. The organic extracts were washed with brine, dried (Na_2SO_4), filtered and concentrated *in vacuo* to afford the crude product. The crude product was purified by chromatography to give the title compound.

Preparation 1

Methyl 1-(4-nitrophenyloxycarbonyl)oxy)methyl succinate (Compound 201).

A solution of iodomethyl 4-nitrophenyl carbonate (3.2 g, 10 mmol)(J. Org. Chem, **1997**, 62, 1356) in dichloromethane (50 ml) was added to a stirred suspension of silver methyl succinate (2.4 g, 10 mmol) in dichloromethane (50 ml). Stirring was continued for 24 hours at room temperature. Filtration and concentration of the residue *in vacuo* gave the crude product. Further purification was performed by chromatography using Et_2O/hexane 4:1 as eluent to give the product as an oil.

Preparation 2

Methyl 1-(4-nitrophenyloxycarbonyl)oxy)ethyl succinate (Compound 202)

By following the procedure of preparation 1, but substituting 1-iodoethyl 4-nitrophenyl carbonate for iodomethyl 4-nitrophenyl carbonate, the desired compound was obtained.

Preparation 3

Benzyl 1-(4-nitrophenyloxycarbonyl)oxy)methyl succinate (Compound 203)

By following the procedure of preparation 1, but substituting silver benzyl succinate for silver methyl succinate, the desired compound was obtained.

Preparation 4

1-(3-(Benzyloxycarbonyl)propanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 204)

By following the procedure of example 21, but substituting benzyl 1-(4-nitrophenyloxycarbonyl)oxy)methyl succinate (Compound 203) for methyl 1-(4-nitrophenyloxycarbonyl)oxy)methyl succinate (Compound 201), the desired compound was obtained. Purification was done by chrormatography using Et_2O/hexane 4:1 as eluent.

Preparation 5

Benzyl 1-(4-nitrophenyloxycarbonyl)oxy)ethyl succinate (Compound 205)

By following the procedure of preparation 1, but substituting silver benzyl succinate and 1-iodoethyl 4-nitrophenyl carbonate for silver methyl succinate and iodomethyl 4-nitrophenyl carbonate respectively, the desired compound was obtained. Purification was done by chromatography using a mixture of EtOAcetate/hexane 1:4.

Preparation 6

1-(3-(Benzyloxycarbonyl)propanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 206)

By following the procedure of example 21, but substituting benzyl 1-(4-nitrophenyloxycarbonyl)oxy)ethyl succinate (Compound 205) for methyl 1-(4-nitrophenyloxycarbonyl)oxy)-methyl succinate (Compound 201), the desired compound was obtained. Purification was done by chrormatography using Et_2O/hexane 4:1 as eluent.

Preparation 7

Hexanoyloxymethyl 4-nitrophenyl carbonate (Compound 207)

By following the procedure of preparation 1, but substituting silver hexanoate for silver methyl succinate, the desired compound was obtained. Purification was done by chromatography using a mixture of methanol/EtOAcetate/hexane 5:10:40.

Preparation 8

1-(Ethylthio(carbonyl)oxy)methyl methyl succinate (Compound 208)

Silver methyl succinate (2.5 g, 10.5 mmol) was added a stirred solution of *O*-iodomethyl *S*-ethyl thiocarbonate (1.25 g, 5.1 mmol)(Synthesis, **1990**, 1159) in dichloromethane (50 ml). Stirring was continued for 24 hours at room temperature. Filtration and concentration of the residue *in vacuo* gave the crude product. Further purification was performed by chromatography using Et_2O/hexane 1:2 as eluent to give the product as an oil.

Preparation 9

O-(3-Methoxycarbonyl-propanoyloxymethyl) carbonochloridate (Compound 209)

Redistilled sulfurylchloride (0.81 ml, 10 mmol) was added to 1-(Ethylthio(carbonyl)oxy)-methyl methyl succinate (Compound 208) (2.5 g, 10 mmol) at 0-5 ^{o}C with stirring during 30 minutes followed by stirring at room temperature for two hours. The reaction mixture was concentrated *in vacuo* for 18 hours to give the title compound as an oil.

Preparation 10

Benzyl 1-(ethylthio(carbonyl)oxy) methyl succinate (Compound 210)

By following the procedure of preparation 8, but substituting silver benzyl succinate for silver methyl succinate, the desired compound was obtained.

Preparation 11

O-(3-Benzyloxycarbonyl-propanoyloxymethyl) carbonochloridate (Compound 211)

By following the procedure of preparation 9, but substituting Benzyl 1-(ethylthio(carbonyl)oxy) methyl succinate (Compound 210) for 1-(Ethylthio(carbonyl)oxy)methyl methyl succinate (Compound 208), the desired compound was obtained.

Preparation 12

1-(3-Benzyloxycarbonyl-propanoyloxy)methyl *N*-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 212)

By following the procedure of example 26, but substituting *O*-(3-benzyloxycarbonyl-propanoyloxymethyl) carbonochloridate (compound 211) for *O*-(3-methoxycarbonyl-propanoyloxymethyl) carbonochloridate (Compound 209), the desired compound was obtained.

Example 1

Hexyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 101)

General procedure: 2

Starting compound II: 4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone

Starting compound VI: 1-Hexanol

Purification: Chromatography using CH_2Cl_2 as eluent

^{13}C NMR ($CDCl_3$): δ 196.9, 154.5, 149.4, 139.3, 138.0, 135.2, 133.7, 133.5, 131.4, 131.0, 130.7, 129.8, 129.0, 126.9, 126.0, 125.5, 125.0, 121.9, 116.3, 112.5, 66.1, 31.6, 29.0, 25.6, 22.7, 20.6, 14.2

Example 2

6-Chloro-hexyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 102)

General procedure: 2

Starting compound II: 4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone

Starting compound VI: 6-Chloro-1-hexanol

Purification: Chromatography using EtOAc/pentane 1:4 as eluent

^{13}C NMR ($CDCl_3$): δ 196.6, 154.2, 149.2, 139.1, 137.9, 135.0, 133.5, 133.3, 131.3, 130.9, 130.5, 129.7, 129.0, 126.8, 125.9, 125.4, 124.8, 121.7, 116.1, 112.4, 65.6, 44.9, 32.4, 28.7, 26.5, 25.2, 20.4

Example 3

Phenyl *N*-[2-(4-benzoylphenylamino)phenyl]carbamate (Compound 103)

General procedure: 1

Starting compound II: 4-(2-Aminophenylamino)benzophenone

Starting compound III: Phenyl chloroformate

Purification: Crystallization from 2-propanol

Mp: 145-146 °C

^{1}H NMR (Acetone-d_6): δ 8.60 (bs,1H), 7.89 (d,1H), 7.84 (m,2H), 7.70 (m,4H), 7.51(m,2H), 7.40 (m,3H), 7.10-7.30 (m,5H), 6.91 (d,2H)

Example 4

2-Azido-ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 104)

General procedure: 2

Starting compound II: 4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone

Starting compound VI: 2-Azido-1-ethanol

Purification: Chromatography using EtOAc/pentane 1:3 as eluent

^{13}C NMR ($CDCl_3$): δ 196.6, 153.4, 149.0, 139.0, 138.0, 135.0, 133.4, 133.0, 131.3, 130.9, 130.6, 129.8, 129.4, 127.0, 126.0, 125.4, 125.2, 121.8, 116.1, 112.6, 64.0, 50.0, 20.5

Example 5

Phenyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 105)

General procedure: 1

Starting compound II: 4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone

Starting compound III: Phenyl chloroformate

Purification: Crystallization from a mixture of toluene and cyclohexane

Mp: 99-108 °C

^{1}H NMR ($CDCl_3$): δ 7.93 (d,1H), 7.10-7.40 (m,14H), 6.76 (d,1H), 6.61 (dd,1H), 5.93 (s,1H), 2.44 (s,3H)

Example 6

1-Chloromethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 106)

To a cooled (0 °C) solution of chloromethyl chloroformate (4.27 mmol) in EtOAc (20 ml) was slowly added a solution of 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone (4.0 mmol) and triethylamine (4.45 mmol) in EtOAc (20 ml) under stirring. Stirring was continued at room temperature for 4 h. The reaction mixture was washed with water and 0.5 M tartaric acid, dried (Na_2SO_4), filtered and concentrated *in vacuo*. The crude product was purified by chromatography using Et_2O/hexane 4:1 as eluent to give the title compound as white crystals.

Mp: 152-153 °C

^1H NMR ($CDCl_3$): δ 7.93 (d,1H), 7.10-7.40 (m,9H), 6.72 (d,1H), 6.57 (dd,1H), 5.83 (s,1H), 5.80 (s,2H), 2.43 (s,3H)

Example 7

Cyclopentyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 107)

General procedure: 1

Starting compound II: 4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: Chromatography using EtOAc/pentane 1:4 as eluent followed by crystallization from Et_2O

Mp: 115-117 °C

^1H NMR (DMSO-d_6): δ 8.65 (s,1H), 8.30 (s,1H), 7.60 (d,1H), 7.42 (m,1H), 7.10-7.40 (m,7H), 6.76 (d,1H), 6.69 (dd,1H), 5.04 (m,1H), 2.29 (s,3H), 1.81 (m,2H), 1.56 (m,6H)

Example 8

Cyclohexyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 108)

General procedure: 1

Starting compound II: 4-(2-Aminophenylamino)-2-chloro-2'-methylbenzophenone

Starting compound III: Cyclohexyl chloroformate

Purification: Crystallization from Et_2O and then trituration in water

Mp: 60-70 °C

^1H NMR (DMSO- d_6): δ 8.67 (s,1H), 8.32 (s,1H), 7.60 (d,1H), 7.41 (m,1H),

7.10-7.35 (m,7H), 6.75 (d,1H), 6.68 (dd,1H), 4.57 (m,1H), 2.29(s,3H), 1.10-1.90 (m,10H)

Example 9

1-Acetoxymethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 109)

To a stirred solution of compound 106 (1.0 mmol) in glacial acetic acid (20 ml) was added AgOAc (3.0 mmol) in one portion. The reaction mixture was stirred for 72 h at room temperature. The reaction mixture was filtered through Decalite, then poured into water and extracted with Et_2O. The organic extracts were washed with saturated $NaHCO_3$, brine, dried (Na_2SO_4), filtered and concentrated *in vacuo* to afford the crude product. The crude product was purified by chromatography using Et_2O/hexane 4:1 as eluent to give the title compound as white crystals.

Mp:145-148 °C

^1H NMR ($CDCl_3$): δ 7.93 (d,1H), 7.10-7.40 (m,9H), 6.70 (d,1H), 6.58 (dd,1H), 5.85 (s,1H), 5.80 (s,2H), 2.44 (s,3H), 2.12 (s,3H)

Example 10

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,3-dimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 110)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2-chloro-2',3'-dimethylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 197.2, 153.6, 149.1, 140.2, 137.9, 135.6, 135.4, 135.2, 134.0, 132.2, 129.1, 128.8, 127.4, 127.3, 126.6, 125.0, 124.0, 119.9, 116.3, 112.4, 79.0, 32.7, 23.6, 20.2, 16.5

Example 11

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-*n*-butyl-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 111)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-4'-*n*-butyl-2-chloro-2'-methylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 196.6, 153.6, 148.5, 146.8, 138.7, 135.9, 135.2, 134.6, 132.9, 131.7, 130.7, 130.1, 129.0, 127.3, 125.4, 123.9, 119.8, 116.2, 112.6, 78.9, 35.6, 33.3, 32.7, 23.7, 22.4, 20.8, 13.9

Example 12

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-chloro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 112)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2,4'-dichloro-2'-methylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 195.5, 153.6, 149.1, 140.1, 137.3, 136.9, 135.1, 135.0, 133.3, 131.3, 131.1, 129.0, 128.9, 127.4, 127.3, 125.6, 124.1, 119.9, 116.1, 112.6, 79.0, 32.7, 23.7, 20.4

Example 13

Cyclopentyl *N*-[5-bromo-2-[3-fluoro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 113)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2-fluoro-2'-methylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 194.5, 163.5, 153.6, 151.5, 140.2, 136.3, 135.1, 133.9, 130.9, 130.3, 128.7, 128.1, 127.5, 127.4, 125.3, 124.2, 120.0, 118.1, 110.3, 101.5, 79.0, 32.7, 23.6, 19.9

Example 14

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,4,5-trimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 114)

General procedure: 1

Starting compound II: 4'-(2-Amino-4-bromophenylamino)-2'-chloro-2,4,5-trimethylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 196.7, 153.6, 148.6, 140.4, 136.1, 135.9, 135.2, 134.6, 133.5, 133.0, 132.9, 131.6, 130.1, 129.1, 127.3, 127.2, 123.9, 119.7, 116.2, 112.5, 78.9, 32.7, 23.7, 20.1, 19.7, 19.1

Example 15

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-fluoro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 115)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2-chloro-4'-fluoro-2'-methyl-benzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 195.4, 164.0, 153.6, 148.9, 141.9, 135.1, 134.9, 134.8, 133.0, 132.6, 129.6, 129.0, 127.4, 127.3, 124.1, 119.9, 118.3, 116.1, 112.7, 112.4, 79.0, 32.7, 23.7, 20.8

Example 16

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,5-dimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 116)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2-chloro-2',5'-dimethyl-benzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 196.9, 153.6, 148.8, 138.8, 135.1, 134.9, 134.8, 133.4, 131.8, 131.2, 130.2, 129.5, 129.0, 127.3, 124.0, 119.9, 116.3, 112.5, 79.0, 32.7, 23.7, 20.8, 20.0

Example 17

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(3-chloro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 117)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2,3'-dichloro-2'-methylbenzo-phenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 195.4, 153.6, 149.5, 141.9, 135.9, 135.7, 135.1, 135.0, 134.2, 131.3, 128.7, 128.2, 127.5, 127.4, 126.9, 126.4, 124.2, 120.0, 116.3, 112.5, 79.1, 32.7, 23.6, 17.1

Example 18

Cyclopentyl *N*-[5-bromo-2-[3-fluoro-4-(4-methoxy-2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 118)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2-fluoro-4'-methoxy-2'-methylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 193.4, 162.9, 161.4, 153.7, 151.1, 140.4, 135.3, 133.4, 132.2, 132.0, 129.0, 127.5, 127.1, 123.9, 119.7, 118.8, 116.7, 110.4, 101.5, 78.8, 55.3, 32.7, 23.7, 20.8

Example 19

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-ethoxy-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 119)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2-chloro-4'-ethoxy-2'-methylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 195.7, 161.5, 153.6, 148.2, 142.1, 135.2, 134.1, 133.8, 132.3, 130.7, 130.5, 129.2, 127.2, 123.8, 119.7, 117.6, 116.0, 112.7, 110.9, 78.9, 63.6, 32.7, 23.7, 21.5, 14.7

Example 20

Cyclopentyl *N*-[5-bromo-2-[3-ethoxy-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 120)

General procedure: 1

Starting compound II: 4-(2-Amino-4-bromophenylamino)-2-ethoxy-2'-methylbenzophenone

Starting compound III: Cyclopentyl chloroformate

Purification: crystallization from Et_2O

^{13}C NMR ($CDCl_3$): δ 197.1, 160.7, 153.6, 150.6, 142.4, 135.8, 135.2, 133.5, 130.4, 129.3, 127.5, 127.4, 127.1, 125.0, 123.8, 120.7, 119.7, 107.2, 98.3, 78.9, 63.8, 32.7, 23.6, 19.9, 13.8

Example 21

1-(3-(Methoxycarbonyl)propanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 121)

A solution of 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone (2.2 g, 6.5 mmol) and methyl 1-(4-nitrophenyloxycarbonyl)oxy)methyl succinate (Compound 201) (3.3 g, 10 mmol) in DMF (100 ml) was added 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (1.7g, 10 mmol) followed by *N*-ethyl di-*iso*-propylamine (1.8 ml, 10.5 mmol). The reaction mixture was stirred at room temperature. After 20 hours, the reaction mixture was poured into ice/water and extracted with diethylether. The etheral extracts were washed with a saturated sodium carbonate solution, water, and brine and dried over anhydrous sodium sulphate. Filtration and concentration *in vacuo* afforded the crude product. This was further purified by chromatography using methanol/EtOAcetate/hexane 5:10:40 as eluent.

^{13}C NMR ($CDCl_3$): δ 196.6, 172.6, 171.4, 152.1, 149.0, 139.0, 138.0, 135.0, 133.4, 132.7, 131.3, 131.0, 129.8, 129.5, 127.0, 126.0, 125.5, 125.4, 121.7, 116.2, 112.6, 80.1, 52.0, 29.0, 28.6, 20.5

Example 22

1-(3-(methoxycarbonyl)propanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenyl-amino]phenyl]carbamate (Compound 122)

By following the procedure of example 21, but substituting methyl 1-(4-nitrophenyloxy-carbonyl)oxy)ethyl succinate (Compound 202) for methyl 1-(4-nitrophenyloxy-carbonyl)oxy)methyl succinate (Compound 201), the desired compound was obtained. Purification was done by chromatography using Et_2O/hexane 4:1 as eluent.

^1H NMR ($CDCl_3$): δ 7.82 (d,1H), 7.42 (m,8H), 6.98 (s,1H), 6.93 (q,1H), 6.79 (d,1H), 6.65 (dd,1H), 6.07 (s,1H), 3.64 (s,3H), 2.64 (m,4H), 2.44 (s,3H), 1.53 (d,3H)

Example 23

1-(3-Carboxypropanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 123)

1-(3-(Benzyloxycarbonyl)propanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 204) (2.2 g, 3.6 mmol) was dissolved in

EtOAcetate (500 ml), 10% Pd on carbon (750 mg) was added, and the reaction mixture was hydrogenated (1 atm) under vigorously shaken until no more starting material remained, as seen on TLC. The reaction mixture was purified by chromatography using a mixture of methanol/chloroform 1:9 to give the title compound.

^{13}C NMR ($CDCl_3$): δ 197.0, 176.7, 171.4, 152.2, 149.1, 138.9, 138.0, 135.0, 133.4, 132.7, 131.3, 131.0, 129.9, 129.2, 127.0, 126.1, 125.4, 121.7, 116.1, 112.5, 80.0, 28.8, 28.5, 20.5

Example 24

1-(3-Carboxypropanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 124)

By following the procedure of example 23, but substituting 1-(3-(benzyloxycarbonyl)-propanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 206) for 1-(3-(Benzyloxycarbonyl)propanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 204), the desired compound was obtained. Purification was done by chrormatography using Et_2O/hexane 4:1 as eluent.

^1H NMR ($CDCl_3$): δ 7.82 (d,1H), 7.43-7.00 (m,9H), 6.91 (q,1H), 6.76 (d,1H), 6.62 (dd,1H), 6.12 (s,1H), 2.62 (s,4H), 2.44 (s,3H), 1.50 (d,3H)

Example 25

1-(hexanoyloxy)methyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 125)

A solution of 4-(2-aminophenylamino)-2-chloro-2'-methylbenzophenone (305 mg, 1.0 mmol) and hexanoyloxymethyl 4-nitrophenyl carbonate (Compound 207) (3.3 g, 10 mmol) in DMF (50 ml) was added 1-hydroxybenzotriazole (270 mg, 2.0 mmol) followed by *N*-ethyl di-*iso*-propylamine (0.18 ml, 1.05 mmol). The reaction mixture was stirred at room temperature. After 72 hours, the reaction mixture was poured into ice/water and extracted with diethylether. The etheral extracts were washed with a saturated sodium carbonate solution, water, and brine and dried over anhydrous sodium sulphate. Filtration and concentration *in vacuo* afforded the crude product. This was further purified by chromatography using Et_2O/hexane 2:1 as eluent.

^1H NMR ($CDCl_3$): δ 7.91 (d,1H), 7.46-7.05 (m,9H), 6.72 (d,1H), 6.60 (dd,1H), 5.88 (s,1H), 5.81 (s,2H), 2.44 (s,3H), 2.37 (t,2H), 1.64 (m,2H), 1.29 (m,4H), 0.87 (t,3H)

Example 26

1-(3-(Methoxycarbonyl)propanoyloxy)methyl *N*-[5-bromo-2-[3-chloro-4-(2-methyl-

benzoyl)-phenylamino]phenyl]carbamate (Compound 126)

Chloro trimethylsilane (0.115 ml, 0.9mmol) was added dropwise to a stirred solution of 4-(2-amino-5-bromophenylamino)-2-chloro-2'-methylbenzophenone (0.75 g, 1.8 mmol) in diethylether (10 ml). After 30 minutes a solution of *O*-(3-methoxycarbonyl-propanoyloxy-methyl) carbonochloridate (Compound 209) (0.25 g, 1.1 mmol) in diethylether (5 ml) was added during 15 minutes followed by stirring at room temperature for 3 hours. Filtration and concentration of the residue *in vacuo* gave the crude product. Further purification was performed by chromatography using Et_2O/hexane 2:1 as eluent to give the product as an oil.

^1H NMR ($CDCl_3$): δ 8.17 (s,1H), 7.50-7.11 (m,8H), 6.72 (d,1H), 6.61 (dd,1H), 5.85 (s,1H), 5.82 (s,2H), 3.66 (s,3H), 2.67 (m,4H), 2.45 (s,3H)

Example 27

1-(3-carboxypropanoyloxy)methyl *N*-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenyl-amino]phenyl]carbamate (Compound 127)

1-(3-(Benzyloxycarbonyl)propanoyloxy)methyl *N*-[5-bromo-2-[3-chloro-4-(2-methyl-benzoyl)-phenylamino]phenyl]carbamate (Compound 212) (580 mg, 0.9 mmol) was dissolved in tetrahydrofurane (50 ml), 10% Pd on carbon (200 mg) was added, and the reaction mixture was hydrogenated (1 atm) under vigorously shaken until no more starting material remained, as seen on TLC. The reaction mixture was purified by chromatography using a mixture of methanol/chloroform 1:9 to give the title compound.

^1H NMR ($CDCl_3$): δ 7.88 (s,1H), 7.46-7.05 (m,8H), 6.72 (d,1H), 6.59 (dd,1H), 6.20 (s,1H), 5.77 (s,2H), 2.61 (s,4H), 2.41 (s,3H)

Example 28

1-Chloromethyl *N*-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 128)

To a cooled (0 °C) solution of chloromethyl chloroformate (0.23 ml, 2.6 mmol) in acetonitrile (10 ml) was slowly added a solution of 4-(2-amino-5-bromophenylamino)-2-chloro-2'-methylbenzophenone (1.04 g, 2.5 mmol) and triethylamine (0.37 ml, 2.6 mmol) in acetonitrile (10 ml) under stirring. Stirring was continued for 1.5 hours. The reaction mixture was filtered and the crude product was dissolved in EtOAcetate. The organic phase was washed with water and brine, dried (Na_2SO_4), filtered and concentrated *in vacuo*. The crude product was purified by crystallization from acetonitrile to give the title compound.

Mp: 189-190 °C

^1H NMR (DMSO- d_6): δ 9.60 (s,1H), 8.43 (s,1H), 7.81 (s,1H), 7.58-7.19 (m,7H), 6.83

(d,1H), 6.74 (dd,1H), 5.94 (s,2H), 2.50 (s,3H)

Example 29 Tablet containing compound 105

Compound 105 (active substance)	50 mg
Lactose	125 mg
Starch	12 mg
Methyl cellulose	2 mg
Sodium carboxymethyl cellulose	10 mg
Magnesium stearate	1 mg

The active substance, lactose and starch are mixed to a homogeneous state in a suitable mixer and moistened with a 5 per cent aqueous solution of methyl cellulose 15 cps. The mixing is continued until granules are formed. If necessary, the wet granulation is passed through a suitable screen and dried to a water content of less than 1% in a suitable drier, e.g. fluid bed or drying oven. The dried granules are passed through a 1 mm screen and mixed to a homogeneous state with sodium carboxymethyl cellulose. Magnesium stearate is added, and the mixing is continued for a short period of time. Tablets with a weight of 200 mg are produced from the granulation by means of a suitable tabletting machine.

Example 30 Formulation for injection containing compound 105.

Compound 105 (active substance)	1%
Sodium chloride	q.s.
Ethanol	10%
Water for injection to make	100%

The active substance is dissolved in ethanol (10%) then water for injection made isotonic with sodium chloride is added to make 100%. The mixture is filled into ampoules and sterilized.

Example 31 Cream formulation containing compound 105.

Compound 105 (10 g) was dissolved in Octyldodecyl myristate (250g) to form Part A. Methylparaben (1 g) and propylparaben (0.2 g) were dissolved in phenoxyethanol (6 g) and mixed with a 0.025 M Phosphate buffer pH = 7.5 (632,8 g) to form Part B. Cetostearyl alcohol (50 g) and ARLACEL 165® (50 g) was melted in a vessel at 70° to 80 °C. Part A was added and heated to 60-70°C. The aqueous phase were likewise heated to 60-70 °C

and slowly added to the melted oil phase under high speed stirring. The homogenized components were cooled to room temperature.

CLAIMS

1. A compound of the general formula I



I

wherein R_1, R_2 and R_3 independently represent one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkyl, (C_2-C_3)olefinic group, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, carbamoyl, or phenyl; R_1 and R_2 further represented by nitro and R_3 by carboxy;

R_4 represents hydrogen, (C_1-C_3)alkyl, or allyl;

Q represents a bond, or -C(R_6)(R_7)(-O-C=O)-, in which formula R_6 and R_7 independently represent hydrogen, trifluoromethyl, or (C_1-C_4)alkyl;

Y represents either (C_5-C_{15})alkyl, (C_2-C_{15})olefinic group, (C_3-C_{10})monocyclic hydrocarbon, or phenyl, any of which may be optionally substituted with one or more, same or different substituents represented by the formula R_5; or (C_1-C_4)alkyl substituted with at least one or more substituents with the formula R_5; or Y represents a group of formula -CH_2-(Z-O)$_n$-Z where Z is a (C_1-C_3)alkyl, where n is a integer > 1 and no continuous linear sequence of atoms in the group Y > 15;

R_5 represents halogen, hydroxy, mercapto, trifluoromethyl, amino, (C_1-C_3)alkoxy, (C_1-C_3)alkylthio, (C_1-C_6)alkylamino, (C_1-C_3)alkoxycarbonyl, cyano, azido, nitro, -COOH, -$CONH_2$, -CONHR', or -COONR'R' wherein R' stands for (C_1-C_3)alkyl;

X represents oxygen or sulphur,

or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.

2. A compound according to claim 1 and selected from the group consisting of compounds wherein

- R_1 represents one or more, same or different substituents selected from the group consisting of fluoro, chloro, bromo, hydroxy, trifluoromethyl, amino, $(C_1$-$C_2)$alkyl, $(C_2$-$C_3)$alkenyl, $(C_1$-$C_3)$alkoxy, $(C_1$-$C_3)$alkoxycarbonyl, or cyano.

- R_2 represents one or more, same or different substituents selected from the group consisting of hydrogen, fluoro, chloro, bromo, hydroxy, trifluoromethyl, amino, $(C_1$-$C_3)$alkyl, $(C_2$-$C_3)$alkenyl, $(C_1$-$C_3)$alkoxy.

- R_3 represents one or more, same or different substituents selected from the group consisting of hydrogen, halogen, hydroxy, trifluoromethyl, $(C_1$-$C_3)$alkyl, $(C_2$-$C_3)$-alkenyl, $(C_1$-$C_3)$alkoxy, $(C_1$-$C_3)$alkoxycarbonyl, cyano, or carboxy.

- R_4 represents hydrogen, $(C_1$-$C_2)$alkyl, or allyl.

- X represents oxygen.

- Q represents a bond or $-CH_2$-O-C=O-.

- Y represents $(C_1$-$C_4)$alkyl substituted with one or more, same or different substituents selected from the group represented by halogen, hydroxy, amino, $(C_1$-$C_2)$alkoxy, $(C_1$-$C_4)$alkylamino, $(C_1$-$C_3)$alkoxycarbonyl, cyano, azido, -COOH, $-CONH_2$, -CONHR', or -CONRR' wherein R and R' represent $(C_1$-$C_2)$alkyl; or Y represents $(C_5$-$C_6)$alkyl; $(C_2$-$C_6)$alkenyl; $(C_3$-$C_6)$cycloalkyl; $(C_5$-$C_8)$cycloalkene group; or phenyl; any of which is optionally substituted with one or more, same or different substituents selected from the group represented by halogen, hydroxy, amino, $(C_1$-$C_2)$alkoxy, $(C_1$-$C_4)$alkyl-amino, $(C_1$-$C_3)$alkoxycarbonyl, cyano, azido, -COOH, $-CONH_2$, -CONHR', or -CONRR' wherein R and R' represent $(C_1$-$C_2)$alkyl.

3. A compound according to claim 1 or 2 wherein one or both of R_1 and R_2 represent one substituent, said substituent preferably being in the ortho position.

4. A compound according to the preceding claim and selected from the group consisting of compounds wherein

- R_1 is 2-methyl
- R_2 is 2-Cl.
- R_3 represents hydrogen.
- R_4 represents hydrogen.
- Y represents (C_1-C_4)alkyl substituted with halogen, hydroxy, amino, cyano, azido, and -COOH, or Y represents (C_5-C_6)alkyl, (C_5-C_6)carbocyclic group, or phenyl any of which may be optionally substituted with one or more, same or different substituents selected from the group consisting of chloro, bromo, hydroxy, amino, azido, (C_1-C_2)alkoxycarbonyl, cyano, -COOH, -$CONH_2$, $CON(CH_3)_2$, in particular methyl, 1-chloro-methyl, 2-azido-ethyl, hexyl, 6-chloro-hexyl, or phenyl.

5. A compound according to claim 1 selected from the group consisting of
2-Azido-ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 104),
Phenyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 105),
Cyclopentyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 107),
Cyclohexyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 108),
1-Acetoxymethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 109),
Cyclopentyl *N*-[5-bromo-2-[3-fluoro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 113),
Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,4,5-trimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 114),
Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(4-fluoro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 115),
Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(2,5-dimethylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 116),

Cyclopentyl *N*-[5-bromo-2-[3-chloro-4-(3-chloro-2-methylbenzoyl)-phenylamino]phenyl]-carbamate (Compound 117),
Cyclopentyl *N*-[5-bromo-2-[3-fluoro-4-(4-methoxy-2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 118),
Cyclopentyl *N*-[5-bromo-2-[3-ethoxy-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 120),
1-(3-(Methoxycarbonyl)propanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenyl-amino]phenyl]carbamate (Compound 122),
1-(3-Carboxypropanoyloxy)ethyl *N*-[2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]-phenyl]carbamate (Compound 124),
1-(3-Carboxypropanoyloxy)methyl *N*-[5-bromo-2-[3-chloro-4-(2-methylbenzoyl)-phenylamino]phenyl]carbamate (Compound 127),
and salts thereof with pharmaceutically acceptable acids, hydrates and solvates.

6. A pharmaceutical composition containing as an active ingredient a compound according to any one of claims 1 to 5 together with a pharmaceutically acceptable carrier and optionally together with a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticolinergic agents, methyl xanthines, β-adrenergic agents, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

7. Use of a compound according to any one of claim 1 to 5 for the preparation of a medicament for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne.

8. A method for the treatment and/or prophylaxis of asthma, allergy, arthritis, including rheumatoid arthritis and spondyloarthritis, gout, atherosclerosis, chronic inflammatory bowel disease (Crohn's disease), proliferative and inflammatory skin disorders, such as psoriasis, atopic dermatitis, uveitis, septic shock, AIDS, osteoporosis and acne, characterised in administering to a patient suffering from at least one of said diseases an effective amount of one or more compounds according to any one of claims 1 to 5 as an active ingredient alone, or if necessary together with a pharmaceutically acceptable carrier, and, optionally, a second active ingredient optionally selected from the group consisting of glucocorticoids, vitamin D's, anti-histamines, platelet activating factor (PAF) antagonists, anticolinergic agents, methyl xanthines, β-adrenergic agents, salicylates,

indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol-reducing agents, retinoids, zinc salts, and salicylazosulfapyridin (Salazopyrin).

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 00/00386

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07C 271/06, A61K 31/27
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9832730 A1 (LEO PHARMACEUTICAL PRODUCTS LTD. A/S), 30 July 1998 (30.07.98) -- --------	1-7

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" erlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 Sept 2000	10.10.2000

Name and mailing address of the International Searching Authority
European Patent Office P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel(+31-70)340-2040, Tx 31 651 epo nl,
Fax(+31-70)340-3016

Authorized officer
GÖRAN KARLSSON/GH
Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK00/00386

Box I **Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:

see extra sheet

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).:

Box II **Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK00/00386

Claim 8 is directed to a diagnostic method or to a method for treatment of the human or animal body by therapy methods practised on the human or animal body, see Rule 39.1 (iv).
Nevertheless, a search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

28/06/00

International application No.
PCT/DK 00/00386

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9832730 A1	30/07/98	AU 2969297 A	05/01/98
		AU 5478198 A	18/08/98
		CN 1248966 T	29/03/00
		EP 0902872 A	24/03/99
		EP 0966424 A	29/12/99
		GB 9701453 D	00/00/00
		PL 334806 A	13/03/00